NCT00292396

Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Subcutaneous Injections of ABT-874 vs. Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 180 (actual)
• Sponsor: AbbVie (prior sponsor, Abbott) · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to assess the safety and efficacy of ABT-874 in the treatment of moderate to severe chronic plaque psoriasis.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Anti IL-12 monoclonal antibody/ABT-874	Please see Arm Description for intervention description and details.
DRUG	placebo	12 doses

Timeline

• Start date: 2005-11-01
• Primary completion: 2008-04-01
• Completion: 2008-04-01
• First posted: 2006-02-16
• Last updated: 2013-01-18

Locations

24 sites across 2 countries: United States, Canada